Last reviewed · How we verify
Anthralin — Competitive Intelligence Brief
marketed
dithranol
Arachidonate 12-lipoxygenase, 12R-type, NAD-dependent protein deacylase sirtuin-5, mitochondrial, Serine protease hepsin
Immunology
Live · refreshed every 30 min
Target snapshot
Anthralin (dithranol).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anthralin TARGET | dithranol | marketed | dithranol | Arachidonate 12-lipoxygenase, 12R-type, NAD-dependent protein deacylase sirtuin-5, mitochondrial, Serine protease hepsin |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (dithranol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anthralin CI watch — RSS
- Anthralin CI watch — Atom
- Anthralin CI watch — JSON
- Anthralin alone — RSS
- Whole dithranol class — RSS
Cite this brief
Drug Landscape (2026). Anthralin — Competitive Intelligence Brief. https://druglandscape.com/ci/dithranol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing